| Drug General Information |
| Drug ID |
D0M1WN
|
| Former ID |
DNC012602
|
| Drug Name |
L-701324
|
| Drug Type |
Small molecular drug
|
| Indication |
Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63]
|
Terminated |
[1],
[2],
[3]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H14ClNO3
|
| InChI |
InChI=1S/C21H14ClNO3/c22-14-9-10-17-18(12-14)23-21(25)19(20(17)24)13-5-4-8-16(11-13)26-15-6-2-1-3-7-15/h1-12H,(H2,23,24,25)
|
| InChIKey |
FLVRDMUHUXVRET-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
6152492, 11113780, 14852666, 24278508, 26751961, 29296662, 46500448, 47734111, 48407477, 50064412, 53859321, 56463203, 57338999, 74478530, 85787790, 91704667, 103202537, 103856997, 103945611, 104397616, 109614211, 124800704, 126433212, 127865846, 134222721, 134349807, 135073053, 135698326, 142472699, 162022759, 162226782, 163772369, 164777554, 170481123, 178101057, 178126151, 179466455, 198983432, 228156678, 241181973, 246643161
|
| Target and Pathway |
| Target(s) |
Glutamate [NMDA] receptor subunit epsilon 1 |
Target Info |
Inhibitor |
[4]
|
|---|
| Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Inhibitor |
[4]
|
| NMDA receptor subunit NR1 |
Target Info |
Inhibitor |
[4]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Glutamatergic synapse
|
|
Dopaminergic synapse
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Nicotine addiction
|
|
Alcoholism
|
|
Systemic lupus erythematosushsa04014:Ras signaling pathway
|
|
Huntington's disease
|
|
PANTHER Pathway
|
Huntington disease
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Pathway Interaction Database
|
Reelin signaling pathwayerbb4_pathway:ErbB4 signaling events
|
|
Reelin signaling pathway
|
|
Reactome
|
Unblocking of NMDA receptor, glutamate binding and activation
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
RAF/MAP kinase cascadeR-HSA-3928662:EPHB-mediated forward signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Alzheimers DiseaseWP666:Hypothetical Network for Drug Addiction
|
|
BDNF signaling pathwayWP706:SIDS Susceptibility Pathways
|
|
Spinal Cord Injury
|
|
BDNF signaling pathway
|
|
Alzheimers Disease
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4240). |
|---|
| REF 2 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. Psychopharmacology (Berl). 1999 Apr;143(3):235-43. |
|---|
| REF 3 | Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther. 1996 Nov;279(2):492-501. |
|---|
| REF 4 | J Med Chem. 2006 Feb 9;49(3):864-71.Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. |
|---|
